Skip to main content

Table 2 Expression of STAT3 and phosphorylated STAT3 [pSTAT3(Y705) and pSTAT3(S727)] in HPV- and HPV16+ precancer and cancer lesions of the uterine cervix as observed by immunoblotting1

From: Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection

Target Protein Normal (n = 20) Precancer (n = 29) Cancer (n = 63) p value
  HPV-(n = 20); (%) HPV-(n = 13); (%) HPV16+(n = 16); (%) HPV-(n = 5); (%) HPV16+(n = 58); (%)  
Expression Level (→) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++)  
STAT3 18
(90%)
2
(10%)
12
(92%)
1
(8%)
6
(37%)
10
(63%)
4
(80%)
1
(20%)
12
(21%)
46
(79%)
0.005a, 0.01b, 0.49c, 0.19d
pSTAT3 (Y705) 19
(95%)
1
(5%)
12
(92%)
1
(8%)
8
(50%)
8
(50%)
4
(80%)
1
(20%)
21
(36%)
37
(64%)
0.01a 0.07b
0.49c
0.47d
pSTAT3
(S727)
19
(95%)
1
(5%)
12
(92%)
1
(8%)
8
(50%)
8
(50%)
4
(80%)
1
(20%)
28
(48%)
30
(52%)
0.11a
0.37b
0.49c
0.87d
  1. 1Arbitrary level of expression in immunoblotting: Strong (S) = (+++); Medium (M) = (++); Weak (W) = (+); Nil/not detectable (N) = (-). Values indicate the distribution of specimens in each category.
  2. p value, probability from Fischer's Exact Test comparing the expression of proteins; a HPV- vs HPV16+ precancer cases, b HPV- vs HPV16+ cancer cases, c HPV- Precancer vs HPV- in cancer cases, d HPV16+ Precancer vs HPV16+ cancer cases.